“The ambition is really to double our sales in the next five to six years,” says the CEO of Canadian Rx and OTC generics manufacturer PharmaScience, Martin Arès.
“It took 40 years to reach CAD1bn ($738m) of sales
‘I Really Could Not Refuse’: Pharmascience CEO Arès Reflects On First Six Months
Canadian Generics Manufacturer Has Ambitions To Double Sales By End Of Decade
Taking over from the son of the company’s founder at the beginning of 2023, Martin Arès, the CEO of Canadian generics manufacturer Pharmascience, talks to Generics Bulletin about investment, international expansion and biosimilars.
